Trigen Holdings AG's Innovative Platelet Adhesion Inhibitor, PR-15, Successfully Completes First-in-Man Phase I Study
Munich, Germany, and London, UK, 1 May 2007 - Trigen, the cardiovascular drug discovery and development company, today announced the successful completion of its first-in-man Phase I study of PR-15, the company's innovative platelet adhesion inhibitor.